Biogen to unveil 76‑week kidney data for Empaveli and felzartamab at ASN Kidney Week
Biogen will present 76‑week results for Empaveli (pegcetacoplan) at the American Society of Nephrology conference in Denver from Oct. 22‑25, 2026. The data indicate that the drug continues to lower protein loss in urine and keep estimated glomerular filtration rate stable in patients with C3 glomerulopathy and primary immune‑complex membranoproliferative glomerulonephritis. The company will also provide updates on felzartamab, its anti‑CD38 antibody under investigation in three Phase 3 trials for antibody‑mediated rejection, IgA nephropathy and primary membranous nephropathy. The FDA recently broadened Empaveli’s U.S. label to include reduction of kidney‑function loss.
Why it matters
The new long‑term data reinforce the clinical profile that supported the recent label expansion, which could increase the eligible patient pool and boost Biogen’s revenue potential. The felzartamab trial updates give investors insight into a pipeline candidate that may address unmet needs in transplant and glomerular diseases.
Key facts
- 1Biogen will present the 76‑week Empaveli results at the ASN Kidney Week conference in Denver, Colorado, from Oct. 22 to Oct. 25, 2026. investors.biogen.com
- 2The 76‑week data show continued reduction of urinary protein and stable eGFR in patients with C3 glomerulopathy and primary IC‑MPGN. investors.biogen.com
- 3Empaveli’s U.S. indication was recently expanded by the FDA to include reduction of kidney‑function loss in adults and adolescents aged 12 years and older with these diseases. investing.com
- 4Felzartamab is being studied in three Phase 3 trials: TRANSCEND (antibody‑mediated rejection), PREVAIL (IgA nephropathy) and PROMINENT (primary membranous nephropathy). investors.biogen.com
- 5Data from the TRANSCEND trial are expected in the first half of 2027. investing.com
- 6Biogen holds exclusive worldwide rights to felzartamab; Sobi has exclusive ex‑U.S. rights for systemic pegcetacoplan, while Biogen retains exclusive U.S. rights. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.